M Lebwohl

Summary

Publications

  1. ncbi request reprint Topical calcitriol is degraded by ultraviolet light
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Invest Dermatol 121:594-5. 2003
  2. doi request reprint Alefacept: where it stands today
    Jinan Chaarani
    Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, NY 10029, USA
    Expert Opin Drug Metab Toxicol 6:355-61. 2010
  3. doi request reprint Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Mark Lebwohl
    Mount Sinai School of Medicine, New York City, New York 10029, USA
    J Am Acad Dermatol 66:731-41. 2012
  4. pmc Psoriasis treatment: traditional therapy
    M Lebwohl
    The Mount Sinai School of Medicine, New York, NY, USA
    Ann Rheum Dis 64:ii83-6. 2005
  5. ncbi request reprint Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Cutis 83:205-12. 2009
  6. ncbi request reprint An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Dermatol 139:719-27. 2003
  7. ncbi request reprint Innovations in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Dermatol 51:S40-1. 2004
  8. ncbi request reprint No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Arch Dermatol 141:861-4. 2005
  9. ncbi request reprint Proven efficacy of tacrolimus for facial and intertriginous psoriasis
    Mark Lebwohl
    Arch Dermatol 141:1154. 2005
  10. ncbi request reprint Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Acad Dermatol 50:714-21. 2004

Collaborators

Detail Information

Publications105 found, 100 shown here

  1. ncbi request reprint Topical calcitriol is degraded by ultraviolet light
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Invest Dermatol 121:594-5. 2003
    ..Calcipotriene, the only vitamin D analog already approved for psoriasis in the USA, has been used successfully in combination with ultraviolet B and psoralen plus ultraviolet A...
  2. doi request reprint Alefacept: where it stands today
    Jinan Chaarani
    Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, NY 10029, USA
    Expert Opin Drug Metab Toxicol 6:355-61. 2010
    ..It selectively reduces CD45RO(+) memory T cells and inhibits T-cell activation. Clinical data support its safety and efficacy in a substantial subset of patients with psoriasis...
  3. doi request reprint Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Mark Lebwohl
    Mount Sinai School of Medicine, New York City, New York 10029, USA
    J Am Acad Dermatol 66:731-41. 2012
    ..Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of moderate-to-severe psoriasis...
  4. pmc Psoriasis treatment: traditional therapy
    M Lebwohl
    The Mount Sinai School of Medicine, New York, NY, USA
    Ann Rheum Dis 64:ii83-6. 2005
    ..Systemic therapies such as methotrexate, retinoids, and ciclosporin are effective for patients with refractory or extensive cutaneous disease...
  5. ncbi request reprint Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Cutis 83:205-12. 2009
    ..Clinical improvement was maintained for up to 52 weeks, with no clinical effect on calcium homeostasis or other relevant laboratory test parameters...
  6. ncbi request reprint An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Dermatol 139:719-27. 2003
    ....
  7. ncbi request reprint Innovations in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Dermatol 51:S40-1. 2004
  8. ncbi request reprint No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Arch Dermatol 141:861-4. 2005
    ..To determine the incidence of cutaneous squamous cell carcinoma (SCC) in patients with rheumatoid arthritis receiving etanercept, a tumor necrosis factor antagonist, for up to 5 years...
  9. ncbi request reprint Proven efficacy of tacrolimus for facial and intertriginous psoriasis
    Mark Lebwohl
    Arch Dermatol 141:1154. 2005
  10. ncbi request reprint Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Acad Dermatol 50:714-21. 2004
    ..The immune system plays a critical role in the development and pathogenesis of actinic keratosis (AK). Imiquimod has been shown to stimulate the cutaneous immune response and be effective for the treatment of nonmelanoma skin cancers...
  11. ncbi request reprint New roles for systemic retinoids
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    J Drugs Dermatol 5:406-9. 2006
    ....
  12. doi request reprint Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Acad Dermatol 63:571-9. 2010
    ..Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight...
  13. ncbi request reprint A clinician's paradigm in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Acad Dermatol 53:S59-69. 2005
    ..Because some degree of therapy will always be necessary, ranging from maintenance of long-term remission to control of acute psoriasis flares, each patient requires an individualized plan...
  14. ncbi request reprint Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
    ..Calcitriol 3 microg/g ointment has demonstrated good clinical efficacy as well as topical and systemic safety when used to treat psoriasis...
  15. doi request reprint Combining systemic retinoids with biologic agents for moderate to severe psoriasis
    Elizabeth C A Smith
    Department of Dermatology, Mount Sinai School of Medicine, New York, USA
    Int J Dermatol 47:514-8. 2008
    ..Although numerous data exist regarding the use of acitretin and biologic agent therapy alone for psoriasis, little is known about the efficacy, safety, and tolerability of acitretin combined with biologic agents...
  16. ncbi request reprint Review of therapy of psoriasis: the prebiologic armamentarium
    David S Aaronson
    Mount Sinai School of Medicine, 5 East 98th Street, Box 1048, New York, NY 10029 6574, USA
    Dermatol Clin 22:379-88, viii. 2004
    ..With the creation of the newer"biologics," however, the treatment of psoriasis is being re-evaluated...
  17. ncbi request reprint Case studies in severe psoriasis: A clinical strategy
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:26-46. 2003
    ..The purpose of the algorithms is to make optimum use of phototherapy, traditional cytotoxic and immunosuppressive agents, retinoids, and newer biologic agents...
  18. ncbi request reprint The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, New York, USA
    Cutis 80:29-40. 2007
    ..It is notable that in subjects who were being treated with a variety of agents, the addition of clobetasol propionate spray 0.05% during the course of the study resulted in improvements in disease severity...
  19. ncbi request reprint Treatment of psoriasis. Part 1. Topical therapy and phototherapy
    M Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    J Am Acad Dermatol 45:487-98; quiz 499-502. 2001
    ..New radiation sources such as lasers have been added to our armamentarium of available therapies and even newer light source-based treatments are being examined...
  20. ncbi request reprint Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis
    M Lebwohl
    Mount Sinai Medical Center, New York, New York 10029, USA
    J Am Acad Dermatol 38:705-11. 1998
    ..A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed...
  21. ncbi request reprint DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage
    H Wei
    Department of Dermatology, Mount Sinai Medical Center, Box 1047, New York, New York 10029, and Department of Environmental Health Sciences, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Biochemistry 37:6485-90. 1998
    ..These results suggest that the intercalation of genistein and estradiol into DNA may alter the DNA structural integrity, interrupt the production of oxidizing species, and subsequently reduce the formation of 8-OHdG by UV radiation...
  22. ncbi request reprint Vitamin D and topical therapy
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, New York, USA
    Cutis 70:5-8. 2002
    ..05% ointment and cream have been shown to be compatible with calcipotriene for up to 2 weeks. The compatibility of calcipotriene and halobetasol permits the use of these agents together...
  23. ncbi request reprint Retrospective analysis of the treatment of psoriasis of the palms and soles
    P I Spuls
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:21-5. 2003
    ..Other biologic agents are likely to be added to this list in the future...
  24. ncbi request reprint Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis
    S Maryles
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:7-16. 2003
    ..This article focuses on the transition for patients with psoriasis being managed with methotrexate and cyclosporine to retinoids, phototherapy, and newer agents...
  25. ncbi request reprint Combination therapy with vitamin D analogues
    S Lamba
    Department of Dermatology, Mount Sinai Medical Center, New York 10029-6574, USA
    Br J Dermatol 144:27-32. 2001
    ..As long as treatments are used correctly, the benefits of combination therapy with vitamin D analogues usually outweigh the few drawbacks...
  26. ncbi request reprint Treatment of psoriasis. Part 2. Systemic therapies
    M Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine of New York University, One Gustave L Levy Place, New York, NY 10029, USA
    J Am Acad Dermatol 45:649-61; quiz 662-4. 2001
    ..Combinations of different treatments are addressed and investigational therapies that are in development are reviewed...
  27. doi request reprint Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
    M Lebwohl
    Mount Sinai School of Medicine, New York, NY, U S A
    Br J Dermatol 162:137-46. 2010
    ..Conclusions Ustekinumab improves HRQoL in patients with moderate-to-severe psoriasis. Patient-reported outcomes measured a treatment effect beyond that indicated by clinical measures...
  28. ncbi request reprint Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis
    M Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York University 10029-6574, USA
    J Am Acad Dermatol 45:544-53. 2001
    ....
  29. doi request reprint Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use
    Amy S Paller
    Department of Dermatology, Northwestern University s Feinberg Medical School Children s Memorial Hospital, 676 North St Clair St, Suite 1600, Chicago, IL 60611, USA
    Pediatrics 122:e1210-8. 2008
    ....
  30. ncbi request reprint The effect of weight on the efficacy of biologic therapy in patients with psoriasis
    Lily Clark
    Department of Dermatology at Columbia University, New York, New York, USA
    J Am Acad Dermatol 58:443-6. 2008
    ..Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight...
  31. ncbi request reprint Tacrolimus ointment is effective for facial and intertriginous psoriasis
    Mark Lebwohl
    Mt Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 51:723-30. 2004
    ..Topical tacrolimus offers the potential for anti-inflammatory effect without the atrophy or other local side effects associated with the use of topical corticosteroids...
  32. ncbi request reprint Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion...
  33. ncbi request reprint Retrospective study of the efficacy of narrowband UVB and acitretin
    P I Spuls
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:17-20. 2003
    ..There is only sparse data on the combination of acitretin with narrowband UVB. We therefore analyzed data on 40 patients treated with this combination...
  34. ncbi request reprint Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice
    H Wei
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Carcinogenesis 19:1509-14. 1998
    ..05). Our results suggest that genistein exerts its anti-initiational and anti-promotional effects on skin carcinogenesis probably through blockage of DNA adduct formation and inhibition of oxidative and inflammatory events in vivo...
  35. ncbi request reprint Acitretin suppression of squamous cell carcinoma: case report and literature review
    M Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:3-6. 2003
    ..Acitretin should be considered as a maintenance therapy for psoriasis patients developing squamous cell carcinomas as a result of PUVA therapy...
  36. ncbi request reprint In vitro compatibility of tazarotene with other topical treatments of psoriasis
    D Hecker
    Department of Dermatology, The Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 42:1008-11. 2000
    ..These results suggest that tazarotene gel can be successfully coprescribed with a range of commonly used topical psoriasis treatments without adversely affecting the chemical stability of either agent...
  37. ncbi request reprint A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cutis 81:517-9. 2008
    ..05% caused a significantly greater reduction in epidermal thickness compared with fluocinonide cream 0.1% when used twice daily for 2 weeks (P<.001). However, neither drug caused significant clinical signs of atrophy...
  38. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  39. ncbi request reprint Newly available treatments for psoriatic arthritis and their impact on skin psoriasis
    Hassan Galadari
    Department of Dermatology, Mt Sinai Medical Center, New York, NY 10029, USA
    Int J Dermatol 42:231-7. 2003
    ..TNF inhibitors represent new therapeutic options for patients with PsA. The potential advantages of treatment with etanercept and infliximab early in the disease course are discussed...
  40. ncbi request reprint Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis
    Charles N Ellis
    Department of Dermatology, University of Michigan Medical School, Ann Arbor 48109 0314, USA
    J Am Acad Dermatol 48:553-63. 2003
    ..Few cost-effectiveness analyses have been conducted on topical therapies for atopic dermatitis...
  41. ncbi request reprint Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I
    David M Pariser
    Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
    J Cutan Med Surg 9:303-12. 2005
    ..Effective psoriasis therapies are needed for long-term symptom control...
  42. ncbi request reprint Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature
    Caroline P Halverstam
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Cutan Med Surg 10:291-9. 2006
    ..Low-dose acitretin has been used for many years as monotherapy or in combination with other systemic therapies for psoriasis. Evidence to date suggests that the frequency of symptomatic bony effects is quite low in these patients...
  43. ncbi request reprint Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo
    H Wei
    Department of Dermatology, The Mount Sinai Medical Center, New York, NY 10029, USA
    Carcinogenesis 19:1013-8. 1998
    ..Our studies suggest that reduction of oxidative damages to biological macromolecules in vitro and in vivo may at least in part explain the anti-carcinogenic and chemopreventive actions of tamoxifen...
  44. ncbi request reprint The use of alefacept in the treatment of psoriasis
    V K Wong
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Skin Therapy Lett 8:1-2, 7. 2003
    ..These findings support the use of alefacept as a viable treatment of psoriasis, without the toxicities associated with some of the current systemic treatments available...
  45. ncbi request reprint Actinic keratosis: epidemiology and progression to squamous cell carcinoma
    M Lebwohl
    Mount Sinai School of Medicine, 5E 98 St, New York, NY 10029, USA
    Br J Dermatol 149:31-3. 2003
    ..There is strong evidence that actinic keratoses can progress to squamous cell carcinoma, underscoring the need to identify and treat patients at risk...
  46. ncbi request reprint Tacrolimus ointment in the treatment of eyelid dermatitis
    Amy Krupnick Freeman
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Cutis 73:267-71. 2004
    ..In addition, none of the patients developed cataracts or glaucoma during the study. In summary, tacrolimus ointment 0.1% may be a safe and effective treatment option for patients with moderate to severe eyelid dermatitis...
  47. ncbi request reprint A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  48. ncbi request reprint Overview on desonide 0.05%: a clinical safety profile
    Vicky Kwan Wong
    Department of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    J Drugs Dermatol 3:393-7. 2004
    ..The excellent safety profile of desonide revealed by this pharmacovigilance program is supported by a review of published clinical trial results...
  49. ncbi request reprint Potential complications associated with the use of biologic agents for psoriasis
    Joshua A Zeichner
    Department of Dermatology, Mount Sinai Medical Center, 5 East 98th Street, Box 1048, New York, NY 10029, USA
    Dermatol Clin 25:207-13, vii. 2007
    ..Both physicians and patients should be aware of the risks involved with each medicine so that the correct drug is chosen to suit each patient...
  50. ncbi request reprint Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies
    Carin H Endzweig-Gribetz
    Department of Dermatology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York 10029, USA
    J Cutan Med Surg 6:12-6. 2002
  51. ncbi request reprint Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas
    Amy Krupnick Freeman
    Mount Sinai School of Medicine, Department of Dermatology, New York, NY 10029, USA
    J Am Acad Dermatol 48:564-8. 2003
    ..In summary, tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both...
  52. ncbi request reprint Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum
    Mark Lebwohl
    Department of Dermatology at the Mount Sinai School of Medicine, USA
    J Am Acad Dermatol 48:620-2. 2003
    ..Mental creases commonly occur in patients with PXE. In young patients they are a sensitive and highly specific physical finding of this disorder. The presence of exaggerated mental creases is, thus, a useful physical marker for PXE...
  53. ncbi request reprint Psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet 361:1197-204. 2003
    ..Enhancements in topical therapy and phototherapy have also increased the armamentarium of treatments available for this disorder...
  54. doi request reprint Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Acad Dermatol 63:775-81. 2010
    ..By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination...
  55. ncbi request reprint Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome
    Marvin J Rapaport
    Department of Dermatology, UCLA School of Medicine, Los Angeles, California, USA
    Clin Dermatol 21:201-14. 2003
  56. ncbi request reprint Treatment of mycosis fungoides with oral bexarotene combined with PUVA
    Dana Kaslow Stern
    Mount Sinai Medical Center, One Gustave L Place, New York, NY 10029, USA
    J Drugs Dermatol 1:134-6. 2002
    ..Our patient's response to a novel regimen of low dose bexarotene combined with PUVA has been excellent and suggests that this regimen may be a useful method for treatment of MF...
  57. ncbi request reprint Combination therapy to treat moderate to severe psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, Mt Sinai Medical Center, 5 E 98th Street, 12th Floor, New York, NY 10029 6574, USA
    J Am Acad Dermatol 50:416-30. 2004
    ....
  58. ncbi request reprint Combining the new biologic agents with our current psoriasis armamentarium
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Am Acad Dermatol 49:S118-24. 2003
    ..Mechanisms of action of the biologic therapies suggest that there is potential for additive benefit when used in combination regimens...
  59. ncbi request reprint A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes
    John Koo
    UCSF Psoriasis and Phototherapy Treatment Center, Department of Dermatology, University of California, San Francisco 94118, USA
    J Am Acad Dermatol 55:637-41. 2006
    ..The merit of topical sequential therapy involving clobetasol foam and calcipotriene ointment has not been experimentally demonstrated...
  60. ncbi request reprint The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey
    G Krueger
    Department of Dermatology, University of Utah Medical School, 50 N Medical Dr, Salt Lake City, UT 84132, USA
    Arch Dermatol 137:280-4. 2001
    ..Physicians may need to improve communication with their patients and should reevaluate their management of psoriasis...
  61. ncbi request reprint Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis
    K Kuroda
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    J Invest Dermatol 116:713-20. 2001
    ....
  62. ncbi request reprint Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography
    E Schwartz
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029
    Exp Mol Pathol 52:63-8. 1990
    ..Furthermore, PXE and normal skin elastins had the same amount of desmosines per milligram purified elastin. This method could be used to evaluate the extent of elastosis or elastolysis in a particular lesion...
  63. ncbi request reprint The penetration of 0.005% fluticasone propionate ointment in eyelid skin
    M H Tan
    Department of Dermatology, The Mount Sinai School of Medicine of New York University, 5 E 98th St, New York, NY 10029, USA
    J Am Acad Dermatol 45:392-6. 2001
    ..618% +/- 0.339% to 1.467% +/- 0.695%). CONCLUSION: Further studies are warranted to examine the safety and efficacy of 0.005% fluticasone propionate ointment for the treatment of eyelid dermatoses...
  64. doi request reprint Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses
    Joshua A Zeichner
    Mount Sinai Medical Center, New York, New York, USA
    J Am Acad Dermatol 60:59-62. 2009
    ..Imiquimod 5% cream applied twice weekly for 16 weeks is effective for treating actinic keratoses but may be limited by local side effects...
  65. ncbi request reprint Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial
    Sewon Kang
    Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Clin Dermatol 6:245-53. 2005
    ..Recently, we conducted a 2-year placebo-controlled study of tretinoin emollient cream 0.05%, including histopathologic assessment of safety and analysis of markers of collagen deposition...
  66. doi request reprint Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
    Robert E Kalb
    Department of Dermatology State University of New York at Buffalo, School of Medicine and Biomedical Science, Buffalo, New York, USA
    J Am Acad Dermatol 60:824-37. 2009
    ..Methotrexate remains a valuable option for the treatment of psoriasis. This report will summarize studies regarding the use of methotrexate since the last guidelines were published in 1998...
  67. ncbi request reprint Imiquimod cream in the treatment of actinic keratoses
    Andrea Persaud
    Department of Dermatology, The Mount Sinai School of Medicine of New York University, New York, NY 1029, USA
    J Am Acad Dermatol 47:S236-9. 2002
    ..Treatments were well tolerated. Imiquimod cream appears to be effective in the treatment of actinic keratoses. The main adverse effect is local inflammation, which can be avoided by reducing the frequency of application...
  68. ncbi request reprint An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis
    Carin H Gribetz
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Acad Dermatol 53:73-5. 2005
    ..The efficacy and safety of one and two courses of alefacept have been demonstrated in phase 2 and 3 clinical trials, with a course of alefacept defined as 12 weeks of once-weekly treatment followed by 12 weeks of observation...
  69. ncbi request reprint Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein
    Huachen Wei
    Department of Dermatology, Box 1047, Mount Sinai School of Medicine, One Gustave Levy Place, 1425 Madison Avenue, New York, NY 10029, USA
    Cancer Lett 185:21-9. 2002
    ..Thus, the antioxidative properties of genistein may explain for the mechanisms of anti-photocarcinogenic action of genistein...
  70. doi request reprint Evaluation of sensory irritation caused by topical medications using a novel technique
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Dermatol 49:269-71. 2010
    ..The aim of this study was to evaluate and compare the sensory irritation caused by hydrocortisone butyrate lipocream 0.1% using a non-invasive and inexpensive technique...
  71. ncbi request reprint Protective effects of lycopene against ultraviolet B-induced photodamage
    Zsuzsanna Fazekas
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nutr Cancer 47:181-7. 2003
    ....
  72. ncbi request reprint Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis
    Julian O Moore
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Carcinogenesis 27:1627-35. 2006
    ..The implications of our findings serve as compelling validation to our conclusions that genistein may serve as a potent chemopreventive agent against photocarcinogenesis...
  73. ncbi request reprint Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas
    H Wei
    Department of Dermatology, Mount Sinai NYU Medical Center, New York, NY 10029, USA
    Free Radic Biol Med 26:1427-35. 1999
    ..The potent scavenging of oxygen species and blocking of UV-induced oxidative DNA damage may, at least in part, explain the mechanism(s) by which green/black teas inhibit photocarcinogenesis...
  74. ncbi request reprint Recent advances in medical dermatology
    Lily N Clark
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Dermatol 46:1005-10. 2007
    ....
  75. ncbi request reprint Mammographic findings in pseudoxanthoma elasticum
    Lionel Bercovitch
    Department of Dermatology, Rhode Island Hospital and Brown Medical School, Providence, USA
    J Am Acad Dermatol 48:359-66. 2003
    ....
  76. ncbi request reprint Use and abuse of topical corticosteroids in infections of the skin and related structures
    Vicky Kwan Wong
    Mount Sinai School of Medicine, 5 East 98th Street, 12th Floor, Box 1048, New York, NY 10029, USA
    J Drugs Dermatol 2:268-76. 2003
    ....
  77. ncbi request reprint A new standardized method of evaluating cutaneous irritation from topical medications
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cutis 82:75-7. 2008
    ..05%, was calculated to be 2.55. Our assay was able to detect and quantify even minimal cutaneous irritation secondary to application of topical medications...
  78. ncbi request reprint Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Dermatol 43:17-20. 2004
    ..Ciclopirox is a synthetic, hydroxypyridone-derived, broad-spectrum antifungal agent with anti-inflammatory properties...
  79. ncbi request reprint The use of systemic immune moderators in dermatology: an update
    Dana Kazlow Stern
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Dermatol Clin 23:259-300. 2005
    ..This article reviews the pharmacology, mechanism of action, side effects, and clinical applications of these therapies...
  80. ncbi request reprint Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage
    Eileen Q Shyong
    Department of Dermatology, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Carcinogenesis 23:317-21. 2002
    ..005). These results indicate that genistein protects the skin from PUVA-induced photodamage...
  81. ncbi request reprint Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris
    M Lebwohl
    Mount Sinai Medical Center, 5 E 98th St, 12th Floor, Box 1048, New York, NY 10029, USA
    Cutis 67:261-6. 2001
    ..We conclude that one week of therapy with terbinafine 1% solution is highly effective, superior to vehicle, and safe for use in superficial fungal infections...
  82. ncbi request reprint Clinical management of psoriasis: principles and practice
    M Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Cutis 67:1-15. 2001
    ..The clinical uses of these agents are illustrated in part through case presentations drawn from the authors' practices, and the supportive role of the National Psoriasis Foundation is reviewed...
  83. ncbi request reprint New cutaneous manifestations of systemic diseases
    S D Khorenian
    Mount Sinai Medical Center, New York, New York
    Am Fam Physician 51:625-30. 1995
    ..Paraneoplastic pemphigus, a recently characterized autoimmune vesicular eruption, produces painful mucocutaneous ulcerations in patients with an occult neoplasm, such as chronic lymphocytic leukemia or malignant lymphoma...
  84. ncbi request reprint Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring
    D W Sherer
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA
    J Am Acad Dermatol 44:534-7. 2001
    ..Therefore all first-degree relatives of affected patients should receive a full dermatologic examination as well as a funduscopic examination. If even mild typical skin or eye findings are present, then skin biopsy should be performed...
  85. ncbi request reprint Acne therapy: clinical pearls
    R H Stein
    Department of Dermatology and Cutaneous Surgery, Mount Sinai Medical Center, New York, NY 10029-6574, USA
    Semin Cutan Med Surg 20:184-9. 2001
    ....
  86. ncbi request reprint Should we switch from combination UVA/UVB phototherapy units to narrowband UVB?
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine of NYU, 5 East 98th Street, Box 1048, New York, NY 10029 6574, USA
    Photodermatol Photoimmunol Photomed 18:44-6; discussion 47-9. 2002
  87. ncbi request reprint Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H-ras gene, but not p53, in SKH-1 hairless mouse skin
    Yongyin Wang
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 116:193-9. 2005
    ..G-->A mutations induced by BaP or BaP-UVA at position 38 of codon 13 have not been reported previously. C-->T transitions were detected in p53 hot spots of exon 8 in 2 of 19 BaP-UVA-induced tumors but were not found in nontumor skin...
  88. ncbi request reprint Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen
    Hassan Galadari
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Dermatol 49:S265-6. 2003
    ..We report 2 patients with pseudoxanthoma elasticum who had characteristic rhytides and horizontal creases of the chin ("mental" creases). Rhytides and horizontal creases were successfully treated with injectable collagen...
  89. ncbi request reprint The combination of benzo[a]pyrene and ultraviolet A causes an in vivo time-related accumulation of DNA damage in mouse skin
    Rao Saladi
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Photochem Photobiol 77:413-9. 2003
    ..80). These results indicate that genetic damage caused by exposures to BaP plus UVA accumulates with time and increases the potential for inductive events leading to carcinogenesis and tumor formation...
  90. ncbi request reprint Impaired skin barrier function in dermatologic disease and repair with moisturization
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Cutis 76:7-12. 2005
    ....
  91. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
    ..Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis...
  92. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  93. ncbi request reprint A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
    Mark Lebwohl
    Mt Sinai School of Medicine, New York 10029 6574, USA
    N Engl J Med 349:2004-13. 2003
    ..Efalizumab, a humanized monoclonal antibody, binds to the alpha subunit (CD11a) of LFA-1 and inhibits the activation of T cells...
  94. ncbi request reprint Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
    Elizabeth J Horn
    National Psoriasis Foundation, Portland, Oregon 97223 7195, USA
    J Am Acad Dermatol 57:957-62. 2007
    ..We sought to assess whether patients with psoriasis with moderate or severe disease are being treated with systemic therapy...
  95. ncbi request reprint A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    Gerald G Krueger
    University of Utah, Salt Lake City, USA
    N Engl J Med 356:580-92. 2007
    ..Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis...
  96. ncbi request reprint New developments in the treatment of psoriasis
    Mark Lebwohl
    Arch Dermatol 138:686-8. 2002
  97. ncbi request reprint Potential future dermatological indications for tacrolimus ointment
    Thomas Ruzicka
    Department of Dermatology, University of Dusseldorf, Moorenstr 5, 40225 Dusseldorf, Germsny
    Eur J Dermatol 13:331-42. 2003
    ..It also provides recommendations for future clinical studies with tacrolimus ointment...
  98. doi request reprint Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle
    Debra Breneman
    University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Am Acad Dermatol 58:990-9. 2008
    ..Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated...
  99. ncbi request reprint Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis
    Jean Paul Ortonne
    hopital l Archet II, 15 Rue de Saint Antoine de Ginestiere, BP 079, Nice, France
    Eur J Dermatol 13:117-23. 2003
    ..These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis...
  100. ncbi request reprint The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
    ..30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses...
  101. ncbi request reprint Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 47:692-700. 2002
    ..The serum half-life of IDEC-114 was approximately 13 days. A single dose of IDEC-114 appears to be safe and well tolerated and has promising clinical activity in psoriasis...